Shares of Zai Lab (09688.HK) plummeted 7.49% in early trading on Friday following the release of its third-quarter earnings report, which fell short of analyst expectations. The biopharmaceutical company's disappointing results have sparked concerns among investors about its near-term growth prospects.

For the quarter ended September 30, Zai Lab reported a loss of 30 cents per share, wider than the 26 cents loss per share analysts had predicted. Revenue also missed the mark, coming in at $115.36 million, a 13.3% year-over-year increase but significantly below the $143.60 million Wall Street had expected. The company's quarterly loss amounted to $35.96 million, highlighting ongoing challenges in achieving profitability.

The earnings miss comes amid a challenging year for Zai Lab, with its shares already down 5.3% year-to-date prior to this latest decline. Despite the setback, Wall Street maintains a generally positive outlook on the stock, with a consensus "buy" rating and a median 12-month price target of $55.00, representing a potential upside of 54.9% from its last closing price. However, investors will be closely watching how the company plans to address its underperformance and return to a growth trajectory in the coming quarters.